• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与严重一氧化碳弥散系数降低相关的情况。

Conditions associated with severe carbon monoxide diffusion coefficient reduction.

机构信息

Hôpital Louis Pradel, Service de Pneumologie - Centre de Référence des Maladies Rares Pulmonaires, France.

出版信息

Respir Med. 2011 Aug;105(8):1248-56. doi: 10.1016/j.rmed.2011.03.004. Epub 2011 Mar 30.

DOI:10.1016/j.rmed.2011.03.004
PMID:21454061
Abstract

OBJECTIVE

To identify conditions associated with severe carbon monoxide transfer coefficient reduction (Kco < 40% of predicted values).

PATIENTS AND METHODS

We retrospectively reviewed pulmonary function tests, such as Kco measurement, in consecutive patients evaluated in the physiology unit of a University hospital over a 6-year period. Patients were included if they had at least 1 measure of severe Kco reduction, with further detailed pulmonary function tests, clinical data, and diagnostic procedures conducted within 6 months.

RESULTS

5576 patients underwent 9061 Kco measurements. 195 patients (3.5%) with Kco < 40% were investigated (156 males; mean age 62 ± 12 years). Mean Kco was 29 ± 9% of predicted values. The main conditions associated with severe Kco reduction were: emphysema (46%); interstitial lung disease (28%); combined pulmonary fibrosis and emphysema (16%); and pre-capillary pulmonary hypertension (8%). Systolic pulmonary artery pressure was ≥ 35 mmHg at echocardiography in 88% of patients. Right heart catheterization performed in 97 patients showed pre-capillary pulmonary hypertension in 86 of 195 patients (44%). Pulmonary hypertension was the most frequent condition associated with Kco severe reduction. Pulmonary hypertension was present in 29%, 53%, and 48% of patients with chronic obstructive pulmonary disease, interstitial lung disease, and combined pulmonary fibrosis and emphysema, respectively, and was disproportionate to the parenchymal lung disease (mean pulmonary artery pressure > 35 mmHg) in 63% of cases.

CONCLUSION

Severe Kco reduction is frequently related to pulmonary hypertension, especially when associated with emphysema and/or interstitial lung disease. Systematic echocardiography is thus warranted in any patient with severe Kco diminution.

摘要

目的

确定与严重一氧化碳转移系数降低(Kco<40%预测值)相关的情况。

患者和方法

我们回顾性分析了在大学医院生理学病房进行的连续患者的肺功能测试,如 Kco 测量。如果患者至少有 1 次严重 Kco 降低的测量值,且在 6 个月内进行了进一步的详细肺功能测试、临床数据和诊断程序,则纳入研究。

结果

5576 例患者进行了 9061 次 Kco 测量。195 例(3.5%)患者 Kco<40%进行了调查(156 例男性;平均年龄 62±12 岁)。平均 Kco 为预测值的 29±9%。与严重 Kco 降低相关的主要情况为:肺气肿(46%);间质性肺疾病(28%);肺纤维化合并肺气肿(16%);以及毛细血管前肺动脉高压(8%)。在 88%的患者中,超声心动图显示收缩压肺动脉压≥35mmHg。在 97 例进行右心导管检查的患者中,195 例患者中有 86 例(44%)存在毛细血管前肺动脉高压。在慢性阻塞性肺疾病、间质性肺疾病和肺纤维化合并肺气肿患者中,肺动脉高压分别是 Kco 严重降低的最常见情况,分别占 29%、53%和 48%,在 63%的病例中与实质肺疾病不成比例(平均肺动脉压>35mmHg)。

结论

严重 Kco 降低常与肺动脉高压相关,尤其是与肺气肿和/或间质性肺疾病相关。因此,在任何严重 Kco 降低的患者中,都应进行系统的超声心动图检查。

相似文献

1
Conditions associated with severe carbon monoxide diffusion coefficient reduction.与严重一氧化碳弥散系数降低相关的情况。
Respir Med. 2011 Aug;105(8):1248-56. doi: 10.1016/j.rmed.2011.03.004. Epub 2011 Mar 30.
2
Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume.调整一氧化碳弥散量(DLCO)和一氧化碳转移系数(KCO)以适应肺泡容积的重要性。
Respir Med. 2000 Jan;94(1):28-37. doi: 10.1053/rmed.1999.0740.
3
Evolution of changes in carbon monoxide transfer factor in men with chronic obstructive pulmonary disease.慢性阻塞性肺疾病男性患者一氧化碳转移因子变化的演变
Respir Med. 2005 Aug;99(8):1053-60. doi: 10.1016/j.rmed.2004.12.009. Epub 2005 Feb 24.
4
Exercise ventilatory inefficiency and mortality in patients with chronic obstructive pulmonary disease undergoing surgery for non-small-cell lung cancer.运动通气效率不足与非小细胞肺癌手术患者的慢性阻塞性肺疾病死亡率相关。
Eur J Cardiothorac Surg. 2010 Jul;38(1):14-9. doi: 10.1016/j.ejcts.2010.01.032. Epub 2010 Mar 30.
5
The discriminatory value of single breath carbon monoxide diffusion coefficient (kCO) in chronic airways obstruction.单次呼吸一氧化碳弥散系数(kCO)在慢性气道阻塞中的鉴别价值。
Bull Physiopathol Respir (Nancy). 1973 Mar-Apr;9(2):473-80.
6
Transfer factor for carbon monoxide: a glance behind the scene.一氧化碳转移因子:幕后一瞥。
Swiss Med Wkly. 2004 Jul 24;134(29-30):413-8. doi: 10.4414/smw.2004.10660.
7
[Behavior of diffusion capacity for carbon monoxide in 2 groups of subjects with pulmonary tuberculosis and chronic obstructive bronchopathy].[两组肺结核合并慢性阻塞性支气管病患者一氧化碳弥散能力的表现]
G Ital Mal Torace. 1970 Jan-Feb;24(1):27-30.
8
Short term variability of single breath carbon monoxide transfer factor.单次呼吸一氧化碳转运因子的短期变异性
Thorax. 2001 May;56(5):358-61. doi: 10.1136/thorax.56.5.358.
9
[Differential diagnostic significance of complex values of gas exchange during submaximal physical effort in patients with emphysema and pulmonary fibrosis].[肺气肿和肺纤维化患者次极量体力活动时气体交换复杂值的鉴别诊断意义]
Pneumologie. 1995 Feb;49(2):65-71.
10
[Measuring breathing pattern in patients with chronic obstructive pulmonary disease by electrical impedance tomography].[通过电阻抗断层成像技术测量慢性阻塞性肺疾病患者的呼吸模式]
Arch Bronconeumol. 2009 Jul;45(7):320-4. doi: 10.1016/j.arbres.2009.01.013. Epub 2009 Jun 3.

引用本文的文献

1
Sensitization to avian and fungal proteins in different work environments.不同工作环境中对禽类和真菌蛋白的致敏作用。
Allergy Asthma Clin Immunol. 2023 Nov 13;19(1):96. doi: 10.1186/s13223-023-00852-w.
2
Resting pulmonary function and artery pressure and cardiopulmonary exercise testing in chronic heart failure patients in Taiwan - a prospective observational cross-sectional study comparing healthy subjects and interstitial lung disease patients.台湾地区慢性心力衰竭患者的静息肺功能、动脉压和心肺运动试验——一项比较健康受试者和间质性肺疾病患者的前瞻性观察性横断面研究。
Ann Med. 2023 Dec;55(1):2228696. doi: 10.1080/07853890.2023.2228696.
3
Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement.
特发性肺纤维化合并肺气肿综合征:美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合官方声明。
Am J Respir Crit Care Med. 2022 Aug 15;206(4):e7-e41. doi: 10.1164/rccm.202206-1041ST.
4
Group 3 Pulmonary Hypertension: From Bench to Bedside.第 3 组肺动脉高压:从基础到临床。
Circ Res. 2022 Apr 29;130(9):1404-1422. doi: 10.1161/CIRCRESAHA.121.319970. Epub 2022 Apr 28.
5
Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis.特发性肺纤维化合并肺气肿对结缔组织疾病和系统性硬化症患者的影响:系统评价和荟萃分析。
Arthritis Res Ther. 2021 Apr 6;23(1):100. doi: 10.1186/s13075-021-02494-y.
6
HRCT diagnosis of combined pulmonary fibrosis and emphysema in a patient of chronic obstructive pulmonary disease with pulmonary hypertension and clinical or radiograph suspicion of pulmonary fibrosis.慢性阻塞性肺疾病合并肺动脉高压且临床或影像学怀疑存在肺纤维化患者的高分辨率计算机断层扫描(HRCT)对联合性肺纤维化和肺气肿的诊断
BJR Case Rep. 2016 Nov 2;2(4):20150070. doi: 10.1259/bjrcr.20150070. eCollection 2016.
7
Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone.合并性肺纤维化和肺气肿(CPFE):一种不同于单纯肺气肿或肺纤维化的病症。
J Thorac Dis. 2015 Apr;7(4):767-79. doi: 10.3978/j.issn.2072-1439.2015.04.17.
8
Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction.合并肺纤维化和肺气肿且伴有或不伴有气流阻塞患者的肺功能损害
Int J Chron Obstruct Pulmon Dis. 2014 Jul 29;9:805-11. doi: 10.2147/COPD.S65621. eCollection 2014.
9
Combined pulmonary fibrosis and emphysema syndrome: a review.肺纤维化合并肺气肿综合征:综述。
Chest. 2012 Jan;141(1):222-231. doi: 10.1378/chest.11-1062.
10
Centrilobular emphysema combined with pulmonary fibrosis results in improved survival: a response.小叶中心型肺气肿合并肺纤维化可提高生存率:一项回应。
Fibrogenesis Tissue Repair. 2011 Jul 25;4:16. doi: 10.1186/1755-1536-4-16.